ArticleHypertension (Dallas, Tex. : 1979)2017
Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/β-Aminopropionitrile-Induced Abdominal Aortic Aneurysm.
Open access · bronzeAbstract read
In one paragraph
Article in Hypertension (Dallas, Tex. : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 52 citations in OpenAlex.
- Lack of endothelial estrogen receptor alpha signaling exacerbates abdominal aortic aneurysm in male mice.American journal of physiology. Heart and circulatory physiology · 2026Article
- Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction.Cardiovascular research · 2026Article
- FGF12 induces aberrant mechanosignaling in aortic smooth muscle cells during thoracic aortic aneurysm formation in Marfan syndrome mice.Experimental & molecular medicine · 2026Article
- ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases.Frontiers in pharmacology · 2025Review
- Glucose transporter 1 in vascular smooth muscle cells is dispensable for abdominal aortic aneurysm induced by angiotensin II.JVS-vascular science · 2025Article
- Olfactory Receptors and Aortic Aneurysm: Review of Disease Pathways.Journal of clinical medicine · 2024Review
- Chronic intermittent hypoxia facilitates the development of angiotensin II-induced abdominal aortic aneurysm in male mice.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Article
- LXRα Promotes Abdominal Aortic Aneurysm Formation Through UHRF1 Epigenetic Modification of miR-26b-3p.Circulation · 2024Article
- β-Aminopropionitrile Induces Distinct Pathologies in the Ascending and Descending Thoracic Aortic Regions of Mice.Arteriosclerosis, thrombosis, and vascular biology · 2024Article
- β-aminopropionitrile Induces Distinct Pathologies in the Ascending and Descending Thoracic Aortic Regions of Mice.bioRxiv : the preprint server for biology · 2024Article
- Effect of Anti-Hypertensive Medication on Plasma Concentrations of Lysyl Oxidase: Evidence for Aldosterone-IL-6-Dependent Regulation of Lysyl Oxidase Blood Concentration.Biomedicines · 2022Article
- Disintegrin and Metalloproteinases (ADAMs [A Disintegrin and Metalloproteinase] and ADAMTSs [ADAMs With a Thrombospondin Motif]) in Aortic Aneurysm.Hypertension (Dallas, Tex. : 1979) · 2022Review
- Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review.Journal of pharmaceutical analysis · 2022Review
- The role of vascular smooth muscle cells in the development of aortic aneurysms and dissections.European journal of clinical investigation · 2022Review
- ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.Advances in pharmacology (San Diego, Calif.) · 2022Article
- Progress in murine models of ruptured abdominal aortic aneurysm.Frontiers in cardiovascular medicine · 2022Review
- Contribution of ADAM17 and related ADAMs in cardiovascular diseases.Cellular and molecular life sciences : CMLS · 2021Review
- Targeting the Extracellular Matrix in Abdominal Aortic Aneurysms Using Molecular Imaging Insights.International journal of molecular sciences · 2021Review
- Targeting mitochondrial fission as a potential therapeutic for abdominal aortic aneurysm.Cardiovascular research · 2021Article
- Inhibition of Peptidyl Arginine Deiminase 4-Dependent Neutrophil Extracellular Trap Formation Reduces Angiotensin II-Induced Abdominal Aortic Aneurysm Rupture in Mice.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Tatsuo KawaiFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Takehiko TakayanagiFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Steven J ForresterFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Kyle J PrestonFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Takashi ObamaFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Toshiyuki TsujiFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Tomonori KobayashiFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Michael J BoyerFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Hannah A CooperFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Hang Fai KwokFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Tomoki HashimotoFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Rosario ScaliaFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.).
Victor RizzoFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.). seguchi@temple.edu rizzov@temple.edu.
Satoru EguchiFrom the Cardiovascular Research Center, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (T. Kawai, T. Takayanagi, S.J.F., K.J.P., T.O., T. Tsuji, T. Kobayashi, M.J.B., H.A.C., R.S., V.R., S.E.); Faculty of Health Sciences, Macau Special Administrative Region, University of Macau, Taipa (H.F.K.); and Department of Anesthesia and Perioperative Care, University of California, San Francisco (T.H.). seguchi@temple.edu rizzov@temple.edu.
University of Macau · MO
Funding
Intracranial Aneurysm Pathogenesis-Roles of Vascular Remodeling and InflammationR01NS055876 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HASHIMOTO, TOMOKI · 2007 to 2015
$3.0MErbB Activation via a Metalloprotease by Angiotensin IIR01HL076770 · NHLBI · VANDERBILT UNIVERSITY · PI EGUCHI, SATORU · 2004 to 2012
$2.8MInflammatory Responses of The Visceral Adipose Tissue MicrocirculationR01DK111042 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI EGUCHI, SATORU, SCALIA, ROSARIO G · 2017 to 2020
$2.3MMechanism of Hypertensive Vascular Remodeling and End-Organ DamageR01HL133248 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI EGUCHI, SATORU · 2016 to 2019
$1.8MThe Role of Mast Cells in the Pathophysiology of Intracranial AneurysmR01NS082280 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HASHIMOTO, TOMOKI · 2013 to 2017
$1.7MVascular signal as a therapeutic target for abdominal aortic aneurysmR01HL128324 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI EGUCHI, SATORU, RIZZO, VICTOR J. · 2015 to 2018
$1.6MIntegrative Mechanisms of Adipose Tissue Dysfunction In obesityR01DK096521 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI SCALIA, ROSARIO G · 2013 to 2016
$1.4MThe Role of Endothelial Dysfunction and Vascular Inflammation in Hypertensive Vascular RemodelingF31HL127971 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI FORRESTER, STEVEN · 2016 to 2016
$27kNHLBI NIH HHS F31 HL127971NHLBI NIH HHS R01 HL076770NHLBI NIH HHS R01 HL128324NHLBI NIH HHS R01 HL133248NIDDK NIH HHS R01 DK096521NIDDK NIH HHS R01 DK111042NINDS NIH HHS R01 NS055876NINDS NIH HHS R01 NS082280
Abstract
Angiotensin II (AngII)-activated epidermal growth factor receptor has been implicated in abdominal aortic aneurysm (AAA) development. In vascular smooth muscle cells (VSMCs), AngII activates epidermal growth factor receptor via a metalloproteinase, ADAM17 (a disintegrin and metalloproteinase domain 17). We hypothesized that AngII-dependent AAA development would be prevented in mice lacking ADAM17 in VSMCs. To test this concept, control and VSMC ADAM17-deficient mice were cotreated with AngII and a lysyl oxidase inhibitor, β-aminopropionitrile, to induce AAA. We found that 52.4% of control mice did not survive because of aortic rupture. All other surviving control mice developed AAA and demonstrated enhanced expression of ADAM17 in the AAA lesions. In contrast, all AngII and β-aminopropionitrile-treated VSMC ADAM17-deficient mice survived and showed reduction in external/internal diameters (51%/28%, respectively). VSMC ADAM17 deficiency was associated with lack of epidermal growth factor receptor activation, interleukin-6 induction, endoplasmic reticulum/oxidative stress, and matrix deposition in the abdominal aorta of treated mice. However, both VSMC ADAM17-deficient and control mice treated with AngII and β-aminopropionitrile developed comparable levels of hypertension. Treatment of C57Bl/6 mice with an ADAM17 inhibitory antibody but not with control IgG also prevented AAA development. In conclusion, VSMC ADAM17 silencing or systemic ADAM17 inhibition seems to protect mice from AAA formation. The mechanism seems to involve suppression of epidermal growth factor receptor activation.
Indexed as
ADAM17 ProteinAortic Aneurysm, AbdominalHypertensionMuscle, Smooth, VascularAminopropionitrileAngiotensin IIAnimalsAorta, AbdominalErbB ReceptorsMiceMice, Inbred C57BLProtein-Lysine 6-OxidaseReceptor Activity-Modifying ProteinsSignal TransductionADAM17 ProteinAdam17 protein, mouseAminopropionitrileAngiotensin IIErbB ReceptorsProtein-Lysine 6-OxidaseReceptor Activity-Modifying Proteinsaneurysmangiotensin IIhypertensionrupturesignal transduction
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.